Adocia (ADOC) Investor Presentation summary

Leadership and team

• Management team renewed, led by CEO Olivier Soula and CFO/COO Mathieu-William Gilbert, with backgrounds at Avadel, Novo Nordisk, KPMG, and Sanofi.

• Team of 80 experts, including 35 PhDs/MDs/PharmDs, based in Lyon, France.

Market focus and challenges

• Focus on diabetes and obesity, addressing chronic pandemics caused by peptide dysregulation.

• Targets mass populations and aims to improve treatment adherence through innovative peptide delivery.

Technology platforms and pipeline

• Four proprietary platforms: BioChaperone®, AdOral®, AdoGel™, and AdoShell® for peptide delivery.

• Pipeline includes clinical and preclinical assets for diabetes, obesity, and cell therapy, with several in partnership or negotiation.